GB2603294A - Developing classifiers for stratifying patients - Google Patents

Developing classifiers for stratifying patients Download PDF

Info

Publication number
GB2603294A
GB2603294A GB2119148.1A GB202119148A GB2603294A GB 2603294 A GB2603294 A GB 2603294A GB 202119148 A GB202119148 A GB 202119148A GB 2603294 A GB2603294 A GB 2603294A
Authority
GB
United Kingdom
Prior art keywords
responsive
subject
therapy
tnf therapy
classifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB2119148.1A
Other languages
English (en)
Other versions
GB202119148D0 (en
Inventor
Ghiassian Susan
R Mellors Theodore
Santolini Marc
Ameli Asher
Schoenbrunner Nancy
R Akmaev Viatcheslav
J Johnson Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scipher Medicine Corp
Original Assignee
Scipher Medicine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipher Medicine Corp filed Critical Scipher Medicine Corp
Publication of GB202119148D0 publication Critical patent/GB202119148D0/en
Publication of GB2603294A publication Critical patent/GB2603294A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
GB2119148.1A 2019-06-27 2020-06-26 Developing classifiers for stratifying patients Withdrawn GB2603294A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962867853P 2019-06-27 2019-06-27
US201962882402P 2019-08-02 2019-08-02
US202062965486P 2020-01-24 2020-01-24
PCT/US2020/039991 WO2020264426A1 (en) 2019-06-27 2020-06-26 Developing classifiers for stratifying patients

Publications (2)

Publication Number Publication Date
GB202119148D0 GB202119148D0 (en) 2022-02-16
GB2603294A true GB2603294A (en) 2022-08-03

Family

ID=74061318

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2119148.1A Withdrawn GB2603294A (en) 2019-06-27 2020-06-26 Developing classifiers for stratifying patients

Country Status (11)

Country Link
US (5) US11195595B2 (https=)
EP (1) EP3990656B1 (https=)
JP (1) JP2022541125A (https=)
KR (1) KR20220044720A (https=)
CN (1) CN114402084A (https=)
AU (1) AU2020308906A1 (https=)
CA (1) CA3145237A1 (https=)
GB (1) GB2603294A (https=)
IL (1) IL289304A (https=)
MX (1) MX2022000128A (https=)
WO (1) WO2020264426A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178546A1 (en) 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
CA3178405A1 (en) 2020-05-14 2021-11-18 Katherine A. OWEN Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus
IL300978A (en) * 2020-09-01 2023-04-01 Scipher Medicine Corp Methods and systems for predicting response to anti-TNF treatments
US11430575B2 (en) * 2020-11-13 2022-08-30 Specialty Diagnostic (SDI) Laboratories, Inc. Systems and methods for a data driven disease test result prediction
US12271832B2 (en) * 2021-02-12 2025-04-08 Tempus Ai, Inc. Artificial intelligence engine for directed hypothesis generation and ranking
IL305934A (en) * 2021-03-19 2023-11-01 Scipher Medicine Corp Methods for classifying and treating patients
EP4338163A4 (en) 2021-05-13 2024-11-06 Scipher Medicine Corporation ASSESSMENT OF RESPONSE TO THERAPY
US20220399092A1 (en) * 2021-06-10 2022-12-15 Rajant Health Inc. Ai-enabled health platform
MX2023015447A (es) * 2021-06-22 2024-05-09 Scipher Medicine Corp Métodos y sistemas para la supervisión de terapias y el diseño de ensayos.
WO2023150731A2 (en) * 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies
CN114861764B (zh) * 2022-04-11 2024-11-22 中国科学院计算技术研究所 基于auc优化的多类别分类方法及系统
CN115206439B (zh) * 2022-05-20 2025-07-18 南开大学 跨语言平台的空间转录组数据转换方法及系统
WO2024081737A1 (en) * 2022-10-12 2024-04-18 Exagen Inc. Biomarker selection for machine learning enabled prediction of treatment response
CN116312796B (zh) * 2022-12-27 2023-11-14 江苏先声医学诊断有限公司 一种基于期望最大化算法的宏基因组丰度估计方法及系统
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160146831A1 (en) * 2006-04-18 2016-05-26 The Board Of Trustees Of The Leland Stanford Junior University Antibody and Cytokine Biomarker Profiling for Determination of Patient Responsiveness
US20190060449A1 (en) * 2011-05-10 2019-02-28 Nestec S.A. Methods of disease activity profiling for personalized therapy management

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
AU2006294477A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
NZ567286A (en) 2005-11-01 2012-03-30 Abbott Biotechnolgy Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
EP2679996A1 (en) 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
JP5719591B2 (ja) 2007-06-08 2015-05-20 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
US7863021B2 (en) 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009102957A2 (en) 2008-02-14 2009-08-20 The Johns Hopkins University Methods to connect gene set expression profiles to drug sensitivity
EP2307563B1 (en) 2008-03-28 2014-08-06 Katholieke Universiteit Leuven KU Leuven Research & Development Mucosal gene signatures
KR20100003759A (ko) 2008-07-02 2010-01-12 양혜지 반짝이가 포함된 구두약
CN102171365B (zh) 2008-08-25 2014-01-29 森托科尔奥索生物科技公司 用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物
WO2010025961A2 (en) 2008-09-03 2010-03-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Computer implemented model of biological networks
EP2337861A4 (en) 2008-10-10 2013-06-26 Mount Sinai Hospital Corp METHOD FOR CLASSIFYING SAMPLES ON NETWORK MODULAR BASIS
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CA2777800C (en) 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US10192641B2 (en) 2010-04-29 2019-01-29 The Regents Of The University Of California Method of generating a dynamic pathway map
EP2564340B1 (en) 2010-04-29 2020-01-08 The Regents of The University of California Pathway recognition algorithm using data integration on genomic models (paradigm)
WO2012066536A2 (en) 2010-11-16 2012-05-24 Prediguard Transcriptome signatures discriminate etanercept-treated rheumatoid arthritis (ra) patients according to their response or refractory status
WO2012101183A2 (en) 2011-01-25 2012-08-02 Tc Land Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs
US20130040835A1 (en) 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
CN104955845B (zh) 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
HU230680B1 (hu) 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
CA2890161A1 (en) 2012-11-05 2014-05-08 Novigenix Sa Biomarker combinations for colorectal tumors
EP2922861A4 (en) 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
US10161936B2 (en) 2013-03-08 2018-12-25 University Of Leipzig Method and kit for cytokine analysis from a human whole blood sample
WO2014186761A2 (en) 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
US20160162657A1 (en) 2013-07-08 2016-06-09 Northeastern University Methods For Identifying Complex Disease Subtypes
CA2922732A1 (en) 2013-09-03 2015-03-12 L. Douglas GRAHAM Treatment methods for rheumatoid arthritis
US20160232279A1 (en) 2013-09-23 2016-08-11 Northeastern University System and Methods for Disease Module Detection
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
CA2943821A1 (en) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
US9753041B2 (en) 2014-04-21 2017-09-05 Univeristy Of South Florida Salivary inflammatory biomarkers associated with glycemic control and oral health
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
CA2969326A1 (en) 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
HK1257443A1 (zh) * 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
WO2017059276A2 (en) * 2015-10-02 2017-04-06 Momenta Pharmaceuticals, Inc. Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation
US10018637B2 (en) 2015-10-06 2018-07-10 Celgene International Ii Sarl Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast
ES2716900T3 (es) 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
US20190080051A1 (en) 2015-11-11 2019-03-14 Northeastern University Methods And Systems For Profiling Personalized Biomarker Expression Perturbations
US20170145501A1 (en) 2015-11-20 2017-05-25 Lasse Folkersen Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response
EP3440579A4 (en) 2015-11-24 2020-03-25 Klaritos, Inc. INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES
GB201521357D0 (en) 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
JP6572120B2 (ja) 2015-12-14 2019-09-04 浜松ホトニクス株式会社 光ビーム照射装置
WO2017151755A1 (en) 2016-03-02 2017-09-08 Crescendo Bioscience Biomarkers and methods for predicting response to discontinuation of inflammatory disease therapy
WO2017223116A2 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
EP3654993A4 (en) 2017-07-17 2021-08-25 The Broad Institute, Inc. CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
US20200165677A1 (en) 2017-07-18 2020-05-28 Thaddeus Stappenbeck Methods and uses of inflammatory bowel disease biomarkers
US10512775B2 (en) * 2017-08-30 2019-12-24 Cochlear Limited Noise reduction for implantable hearing prostheses
US20190287644A1 (en) 2018-02-15 2019-09-19 Northeastern University Correlation Method To Identify Relevant Genes For Personalized Treatment Of Complex Disease
WO2019178546A1 (en) 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
EA202191354A1 (ru) 2018-11-15 2021-08-11 Янссен Байотек, Инк. Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
AU2020244763A1 (en) 2019-03-22 2021-09-30 Inflammatix, Inc. Systems and methods for deriving and optimizing classifiers from multiple datasets
CN114026644A (zh) 2019-03-28 2022-02-08 相位基因组学公司 通过测序进行核型分析的系统和方法
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
IL300978A (en) 2020-09-01 2023-04-01 Scipher Medicine Corp Methods and systems for predicting response to anti-TNF treatments
IL305934A (en) 2021-03-19 2023-11-01 Scipher Medicine Corp Methods for classifying and treating patients
WO2023150731A2 (en) 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160146831A1 (en) * 2006-04-18 2016-05-26 The Board Of Trustees Of The Leland Stanford Junior University Antibody and Cytokine Biomarker Profiling for Determination of Patient Responsiveness
US20190060449A1 (en) * 2011-05-10 2019-02-28 Nestec S.A. Methods of disease activity profiling for personalized therapy management

Also Published As

Publication number Publication date
US12062415B2 (en) 2024-08-13
EP3990656A1 (en) 2022-05-04
US20220101946A1 (en) 2022-03-31
JP2022541125A (ja) 2022-09-22
AU2020308906A1 (en) 2022-02-03
EP3990656A4 (en) 2023-12-06
CN114402084A (zh) 2022-04-26
US11456056B2 (en) 2022-09-27
GB202119148D0 (en) 2022-02-16
US11195595B2 (en) 2021-12-07
US20230386606A1 (en) 2023-11-30
US20210280271A1 (en) 2021-09-09
KR20220044720A (ko) 2022-04-11
EP3990656B1 (en) 2026-04-22
CA3145237A1 (en) 2020-12-30
US20240355416A1 (en) 2024-10-24
IL289304A (en) 2022-02-01
MX2022000128A (es) 2022-04-27
WO2020264426A1 (en) 2020-12-30
US11783913B2 (en) 2023-10-10
US20220375541A1 (en) 2022-11-24
US12525318B2 (en) 2026-01-13

Similar Documents

Publication Publication Date Title
GB2603294A (en) Developing classifiers for stratifying patients
Brown et al. NCCN guidelines insights: acute lymphoblastic leukemia, Version 1.2019: featured updates to the NCCN guidelines
AU2024205632B2 (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
Petri et al. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus
JPWO2020264426A5 (https=)
JP2021518432A5 (https=)
GB2622147A (en) Methods of classifying and treating patients
CA3119749A1 (en) Machine learning disease prediction and treatment prioritization
Zhou et al. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma
JP2021503149A (ja) がん治療の有効性を予測するためのシステムおよび方法
Thomson et al. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis
JP2021505976A (ja) 薬効を評価するためのシステム及び方法
Darrah et al. Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis
Lewis et al. Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism
Ye et al. Clustering the clinical course of chronic urticaria using a longitudinal database: effects on urticaria remission
GB2616129A (en) Methods and systems for predicting response to anti-TNF therapies
Bensalem et al. CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis
Sugiyama et al. Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis
Mease et al. Treatment responses in patients with psoriatic arthritis axial disease according to human leukocyte antigen‐B27 status: an analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
JPWO2019178546A5 (https=)
Mallardo et al. Gene-expression signature predicts autoimmune toxicity in metastatic melanoma
Cappelli et al. Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis
Radich et al. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
Castrejon et al. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate
US20240105303A1 (en) Processes for predicting therapy benefits

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)